

SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC


Revision Date 25-Jun-2024

Revision Number 1.2

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Product identifier

Product Name Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

DocuSigned by:

1A130E8E320B4AF...
2024-07-08

Other means of identification

Catalog Number 60017FI 60017FI.1

Document Number DX22169

Synonym None

Recommended use of the chemical and restrictions on use

Recommended Use Laboratory reagent

Details of the supplier of the safety data sheet

Manufacturer/Supplier

STEMCELL Technologies Canada Inc.
Suite 500 - 1618 Station Street
Vancouver, British Columbia V6A 1B6 Canada

Emergency telephone number

Emergency Telephone 1-800-667-0322

2. HAZARDS IDENTIFICATION

Classification

This chemical is not considered hazardous by the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200)


Hazards not otherwise classified (HNOC)

Not applicable

Label elements

Hazard statements

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)



SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

Revision Date 25-Jun-2024
Revision Number 1.2

The product contains no substances which at their given concentration, are considered to be hazardous to health.

Appearance Clear

Physical state Liquid

Odor No data available

Other Information

Not Applicable

Unknown acute toxicity

0 % of the mixture consists of ingredient(s) of unknown toxicity

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity

100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance

Not applicable.

Mixture

Not a hazardous substance or mixture according to the Globally Harmonized System (GHS)

*The exact percentage (concentration) of composition has been withheld as a trade secret.

4. FIRST AID MEASURES

Description of first aid measures

Inhalation


Remove to fresh air.

Eye contact

Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids.
Consult a physician.

Skin contact

Wash skin with soap and water.



SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

Revision Date 25-Jun-2024

Revision Number 1.2

Ingestion Clean mouth with water and drink afterwards plenty of water.

Most important symptoms and effects, both acute and delayed

Symptoms No information available.

Indication of any immediate medical attention and special treatment needed

Note to physicians Treat symptomatically.

5. FIRE-FIGHTING MEASURES

Suitable Extinguishing Media Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media CAUTION: Use of water spray when fighting fire may be inefficient.

Specific hazards arising from the chemical No information available.

Explosion data

Sensitivity to Mechanical Impact None.
Sensitivity to Static Discharge None.

Special protective equipment for fire-fighters Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures


Personal precautions Ensure adequate ventilation.

Environmental precautions

Environmental precautions See Section 12 for additional Ecological Information.

Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.



SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

Revision Date 25-Jun-2024

Revision Number 1.2

Methods for cleaning up Pick up and transfer to properly labeled containers.

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

7. HANDLING AND STORAGE

Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice.

Conditions for safe storage, including any incompatibilities Store in accordance with information listed on the Product Information Sheet (PIS).

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Control parameters

Exposure Limits This product, as supplied, does not contain any hazardous materials with occupational exposure limits established by the region specific regulatory bodies.

Appropriate engineering controls

Engineering controls Showers
Eyewash stations
Ventilation systems.


Individual protection measures, such as personal protective equipment

Eye/face protection No special protective equipment required.

Skin and body protection No special protective equipment required.

Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are exceeded or irritation is experienced, ventilation and evacuation may be required.

General hygiene considerations Handle in accordance with good industrial hygiene and safety practice.



SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

Revision Date 25-Jun-2024

Revision Number 1.2

9. PHYSICAL AND CHEMICAL PROPERTIES

Information on basic physical and chemical properties

Physical state	Liquid
Appearance	Clear
Color	No information available
Odor	No data available
Odor threshold	No data available

<u>Property</u>	<u>Values</u>	<u>Remarks • Method</u>
pH	No data available	None known
Melting point / freezing point	No data available	None known
Boiling point / boiling range	No data available	None known
Flash point	No data available	None known
Evaporation rate	No data available	None known
Flammability (solid, gas)	No data available	None known
Flammability Limit in Air		None known
Upper flammability limit:	No data available	
Lower flammability limit:	No data available	
Vapor pressure	No data available	None known
Vapor density	No data available	None known
Relative density	No data available	None known
Water solubility	No data available	None known
Solubility in other solvents	No data available	None known
Partition coefficient	No data available	None known
Autoignition temperature	No data available	None known
Decomposition temperature	No data available	None known
Kinematic viscosity	No data available	None known
Dynamic viscosity	No data available	None known
Explosive properties	No data available	
Oxidizing properties	No information available	


Other Information

Softening point	No information available
Molecular weight	No information available
Molecular formula	No information available
VOC Content (%)	No information available
Liquid Density	No information available
Bulk density	No information available

10. STABILITY AND REACTIVITY

Reactivity No information available.

Chemical stability Stable under recommended transport or storage conditions.



SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

Revision Date 25-Jun-2024

Revision Number 1.2

Possibility of hazardous reactions None under normal processing.

Conditions to avoid None known based on information supplied.

Incompatible materials None known based on information supplied.

Hazardous decomposition products None known based on information supplied.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Product Information

Inhalation Specific test data for the substance or mixture is not available.

Eye contact Specific test data for the substance or mixture is not available.

Skin contact Specific test data for the substance or mixture is not available.

Ingestion Specific test data for the substance or mixture is not available.

Symptoms related to the physical, chemical and toxicological characteristics

Symptoms No information available.

Numerical measures of toxicity

Acute toxicity

The following values are calculated based on chapter 3.1 of the GHS document

Unknown acute toxicity 0 % of the mixture consists of ingredient(s) of unknown toxicity

0 % of the mixture consists of ingredient(s) of unknown acute oral toxicity

100 % of the mixture consists of ingredient(s) of unknown acute dermal toxicity

100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (gas)


100 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (vapor)

0 % of the mixture consists of ingredient(s) of unknown acute inhalation toxicity (dust/mist)

Product Information

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation No information available.



SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

Revision Date 25-Jun-2024

Revision Number 1.2

Product Information

Serious eye damage/eye irritation No information available.

Product Information

Respiratory or skin sensitization No information available.

Product Information

Germ cell mutagenicity No information available.

Product Information

Carcinogenicity No information available.

Reproductive toxicity No information available.

Product Information

STOT - single exposure No information available.

Product Information

STOT - repeated exposure No information available.

Product Information

Aspiration hazard No information available.

12. ECOLOGICAL INFORMATION

Ecotoxicity

Product Information

Persistence and degradability No information available.


Bioaccumulation There is no data for this product.

Other adverse effects No information available.

13. DISPOSAL CONSIDERATIONS

Waste treatment methods

Waste from residues/unused products Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.



SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

Revision Date 25-Jun-2024

Revision Number 1.2

Contaminated packaging Do not reuse empty containers.

US EPA Waste Number P105

14. TRANSPORT INFORMATION

DOT

TDG Not regulated

MEX Not regulated

ICAO (air) Not regulated

IATA Not regulated

IMDG Not regulated

RID Not regulated

ADR Not regulated

ADN Not regulated

15. REGULATORY INFORMATION

International Inventories

TSCA	Complies
DSL/NDSL	Complies
EINECS/ELINCS	Complies
ENCS	Does not comply
IECSC	Complies
KECL	Complies
PICCS	Complies
AICS	Complies

Legend:


TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances



SAFETY DATA SHEET

60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5, FITC

Revision Date 25-Jun-2024

Revision Number 1.2

KECL - Korean Existing and Evaluated Chemical Substances
PICCS - Philippines Inventory of Chemicals and Chemical Substances
AICS - Australian Inventory of Chemical Substances

US Federal Regulations

SARA 313

Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40 of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazard Categories

Acute health hazard	No
Chronic Health Hazard	No
Fire hazard	No
Sudden release of pressure hazard	No
Reactive Hazard	No

CWA (Clean Water Act)

This product does not contain any substances regulated as pollutants pursuant to the Clean Water Act (40 CFR 122.21 and 40 CFR 122.42).

CERCLA

This material, as supplied, does not contain any substances regulated as hazardous substances under the Comprehensive Environmental Response Compensation and Liability Act (CERCLA) (40 CFR 302) or the Superfund Amendments and Reauthorization Act (SARA) (40 CFR 355). There may be specific reporting requirements at the local, regional, or state level pertaining to releases of this material.


US State Regulations

California Proposition 65

This product does not contain any Proposition 65 chemicals.

U.S. State Right-to-Know Regulations

Chemical name	New Jersey	Massachusetts	Pennsylvania
Water 7732-18-5	-	-	X
Sodium Phosphate Dibasic 7558-79-4	X	X	X
Sodium Azide 26628-22-8	X	X	X



SAFETY DATA SHEET

**60017FI 60017FI.1 - Anti-Mouse CD4 Antibody, Clone RM4-5,
FITC**

Revision Date 25-Jun-2024

Revision Number 1.2

U.S. EPA Label Information

EPA Pesticide Registration Number Not applicable

16. OTHER INFORMATION, INCLUDING DATE OF PREPARATION OF THE LAST REVISION

Prepared By, Quality Control, STEMCELL Technologies Canada Inc.

Revision Date 25-Jun-2024

Revision Note No information available.

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text. STEMCELL Technologies Inc. shall not be held liable for any damage resulting from handling or from contact with the product.

End of Safety Data Sheet

Certificate Of Completion

Envelope Id: 92D3950E0DE949F797F3AB675CFC533E
 Subject: Complete with DocuSign: DX22169-SDS_1_2_0.pdf
 Source Envelope:
 Document Pages: 10
 Certificate Pages: 5
 AutoNav: Enabled
 Envelope Stamping: Enabled
 Time Zone: (UTC-08:00) Pacific Time (US & Canada)

Status: Completed
 Envelope Originator:
 Cory Thomson
 1618 Station Street
 Suite 500
 Vancouver, BC V6A 1B6
 cory.thomson@stemcell.com
 IP Address: 50.92.193.176

Record Tracking

Status: Original 2024-07-08 13:18	Holder: Cory Thomson cory.thomson@stemcell.com	Location: DocuSign
--	---	--------------------

Signer Events**Signature****Timestamp**

Ruth Gill
ruth.gill@stemcell.com
Program Lead, Official Documentation
Security Level: Email, Account Authentication
(None)



Sent: 2024-07-08 | 13:18
 Viewed: 2024-07-08 | 13:35
 Signed: 2024-07-08 | 13:35

Signature Adoption: Pre-selected Style
 Using IP Address: 50.68.18.181

Electronic Record and Signature Disclosure:

Accepted: 2023-10-06 | 11:37
 ID: 67ca97d0-c1e4-4718-a39b-0e991cdebbac

In Person Signer Events**Signature****Timestamp****Editor Delivery Events****Status****Timestamp****Agent Delivery Events****Status****Timestamp****Intermediary Delivery Events****Status****Timestamp****Certified Delivery Events****Status****Timestamp****Carbon Copy Events****Status****Timestamp**

Sharon McAuliffe
sharon.mcauliffe@stemcell.com

COPIED

Sent: 2024-07-08 | 13:35

Security Level: Email, Account Authentication
(None)

Electronic Record and Signature Disclosure:

Accepted: 2024-05-15 | 15:41
 ID: d2968336-dfa0-4def-b5e9-dc24f64b097a

Paula Liao

paula.liao@stemcell.com

COPIED

Sent: 2024-07-08 | 13:35

Security Level: Email, Account Authentication
(None)

Viewed: 2024-07-08 | 14:42

Electronic Record and Signature Disclosure:

Accepted: 2023-11-02 | 09:10
 ID: 148d0431-20ea-4ee7-af98-97381b674b91

Carbon Copy Events	Status	Timestamp
QAS Document Control qasdocumentcontrol@stemcell.com Security Level: Email, Account Authentication (None)	COPIED	Sent: 2024-07-08 13:35
Electronic Record and Signature Disclosure: Not Offered via DocuSign		
Witness Events	Signature	Timestamp
Notary Events	Signature	Timestamp
Envelope Summary Events	Status	Timestamps
Envelope Sent	Hashed/Encrypted	2024-07-08 13:18
Certified Delivered	Security Checked	2024-07-08 13:35
Signing Complete	Security Checked	2024-07-08 13:35
Completed	Security Checked	2024-07-08 13:35
Payment Events	Status	Timestamps
Electronic Record and Signature Disclosure		

ELECTRONIC RECORD AND SIGNATURE DISCLOSURE

From time to time, Stemcell Technologies Inc (we, us or Company) may be required by law to provide to you certain written notices or disclosures. Described below are the terms and conditions for providing to you such notices and disclosures electronically through the DocuSign system. Please read the information below carefully and thoroughly, and if you can access this information electronically to your satisfaction and agree to this Electronic Record and Signature Disclosure (ERSD), please confirm your agreement by selecting the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

Getting paper copies

At any time, you may request from us a paper copy of any record provided or made available electronically to you by us. You will have the ability to download and print documents we send to you through the DocuSign system during and immediately after the signing session and, if you elect to create a DocuSign account, you may access the documents for a limited period of time (usually 30 days) after such documents are first sent to you. After such time, if you wish for us to send you paper copies of any such documents from our office to you, you will be charged a \$0.00 per-page fee. You may request delivery of such paper copies from us by following the procedure described below.

Withdrawing your consent

If you decide to receive notices and disclosures from us electronically, you may at any time change your mind and tell us that thereafter you want to receive required notices and disclosures only in paper format. How you must inform us of your decision to receive future notices and disclosure in paper format and withdraw your consent to receive notices and disclosures electronically is described below.

Consequences of changing your mind

If you elect to receive required notices and disclosures only in paper format, it will slow the speed at which we can complete certain steps in transactions with you and delivering services to you because we will need first to send the required notices or disclosures to you in paper format, and then wait until we receive back from you your acknowledgment of your receipt of such paper notices or disclosures. Further, you will no longer be able to use the DocuSign system to receive required notices and consents electronically from us or to sign electronically documents from us.

All notices and disclosures will be sent to you electronically

Unless you tell us otherwise in accordance with the procedures described herein, we will provide electronically to you through the DocuSign system all required notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you during the course of our relationship with you. To reduce the chance of you inadvertently not receiving any notice or disclosure, we prefer to provide all of the required notices and disclosures to you by the same method and to the same address that you have given us. Thus, you can receive all the disclosures and notices electronically or in paper format through the paper mail delivery system. If you do not agree with this process, please let us know as described below. Please also see the paragraph immediately above that describes the consequences of your electing not to receive delivery of the notices and disclosures electronically from us.

How to contact Stemcell Technologies Inc:

You may contact us to let us know of your changes as to how we may contact you electronically, to request paper copies of certain information from us, and to withdraw your prior consent to receive notices and disclosures electronically as follows:

To contact us by email send messages to: mark.schuetz@stemcell.com

To advise Stemcell Technologies Inc of your new email address

To let us know of a change in your email address where we should send notices and disclosures electronically to you, you must send an email message to us at mark.schuetz@stemcell.com and in the body of such request you must state: your previous email address, your new email address. We do not require any other information from you to change your email address.

If you created a DocuSign account, you may update it with your new email address through your account preferences.

To request paper copies from Stemcell Technologies Inc

To request delivery from us of paper copies of the notices and disclosures previously provided by us to you electronically, you must send us an email to mark.schuetz@stemcell.com and in the body of such request you must state your email address, full name, mailing address, and telephone number. We will bill you for any fees at that time, if any.

To withdraw your consent with Stemcell Technologies Inc

To inform us that you no longer wish to receive future notices and disclosures in electronic format you may:

- i. decline to sign a document from within your signing session, and on the subsequent page, select the check-box indicating you wish to withdraw your consent, or you may;
- ii. send us an email to mark.schuetz@stemcell.com and in the body of such request you must state your email, full name, mailing address, and telephone number. We do not need any other information from you to withdraw consent.. The consequences of your withdrawing consent for online documents will be that transactions may take a longer time to process..

Required hardware and software

The minimum system requirements for using the DocuSign system may change over time. The current system requirements are found here: <https://support.docusign.com/guides/signer-guide-signing-system-requirements>.

Acknowledging your access and consent to receive and sign documents electronically

To confirm to us that you can access this information electronically, which will be similar to other electronic notices and disclosures that we will provide to you, please confirm that you have read this ERSD, and (i) that you are able to print on paper or electronically save this ERSD for your future reference and access; or (ii) that you are able to email this ERSD to an email address where you will be able to print on paper or save it for your future reference and access. Further, if you consent to receiving notices and disclosures exclusively in electronic format as described herein, then select the check-box next to 'I agree to use electronic records and signatures' before clicking 'CONTINUE' within the DocuSign system.

By selecting the check-box next to 'I agree to use electronic records and signatures', you confirm that:

- You can access and read this Electronic Record and Signature Disclosure; and
- You can print on paper this Electronic Record and Signature Disclosure, or save or send this Electronic Record and Disclosure to a location where you can print it, for future reference and access; and
- Until or unless you notify Stemcell Technologies Inc as described above, you consent to receive exclusively through electronic means all notices, disclosures, authorizations, acknowledgements, and other documents that are required to be provided or made available to you by Stemcell Technologies Inc during the course of your relationship with Stemcell Technologies Inc.